Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles
On September 30, 2020, Pulmatrix (NASDAQ: PULM) announced data from partner Sensory Cloud showcasing the efficacy of FEND, a nasal mist product, in reducing bioaerosol generation. The study revealed that FEND reduced exhaled particles by approximately 75%, outperforming surgical masks. The publication was co-authored by notable researchers including Dr. David Edwards and Dr. Robert Langer. Pulmatrix licensed its NasoCalm formulations to Sensory Cloud, which will market FEND and provide Pulmatrix with escalating royalties upon sales commencement.
- FEND reduced exhaled particles by approximately 75%, significantly outperforming masks.
- FEND may improve hygiene post-pandemic, enhancing market potential.
- Pulmatrix set to receive escalating royalties from Sensory Cloud upon product sales.
- None.
LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the publication of data from partner Sensory Cloud detailing the utility of FEND, a hypertonic calcium chloride salt solution with nasal mister, in the reduction of bioaerosol generation in the airways. Pulmatrix licensed the rights to the Company's NasoCalm proprietary formulations (PUR003 and PUR006) to Sensory Cloud, now integral to the product FEND, with Sensory Cloud to market and distribute FEND, and Pulmatrix to receive escalating royalties, upon commencement of sales.
The publication, titled "Nasal Calcium-Rich Salts for Cleaning Airborne Particles from the Airways of Essential Workers, Students and a Family in Quarantine" and published in the journal Molecular Frontiers, was co-authored by Dr. David Edwards of Harvard (founder of Sensory Cloud), Dr. Robert Langer of MIT, and colleagues. Key findings of the study include:
- In studies across adults and children, FEND nasal salt aerosols lowered exhaled particles by approximately
75% and outperformed surgical masks in the clearing of sub-micron particles - The majority of particles exhaled during natural breathing are smaller in size than current hygiene practices, including face masks and social distancing, are designed to block
- Consistent with classical "super spreading" distributions, approximately
20% of subjects identified as Super Spreaders (of airborne particles), account for80% of the overall exhaled aerosols - FEND delivery suppressed exhaled aerosols 30 minutes post treatment by
78% overall for all (non-Covid-19) Super Spreaders - FEND administration led to a similar reduction in bioaerosol production in a COVID-19 patient who appeared to develop with her infection an acute increase in bioaerosol production consistent with Super Spreader status
"We are pleased to announce the publication of data from our partners at Sensory Cloud which demonstrate the utility of FEND to reduce bioaerosol production across a diverse set of subjects," said Ted Raad, Chief Executive Officer of Pulmatrix. "FEND, originally developed as NasoCALM by Pulmatrix, was shown, in combination with Sensory Cloud's FEND Mister, to effectively reduce exhaled particles even in subjects who were Super Spreaders, as well as a COVID-19 patient with acutely increased bioaerosol production. Importantly, administration of FEND reduces even the smallest aerosol particles which are not blocked by current hygiene practices including mask wearing and social distancing. These data further increase our confidence that FEND may be an important new option to improve hygiene in the wake of the pandemic and we look forward to continued progress as Sensory Cloud advances its plans for commercial launch on a global scale."
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) on the Company's ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates, including the failure to maintain our collaboration with Cipla Technologies, LLC; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission on March 26, 2020 as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Timothy McCarthy, CFA
212.915.2564
tim@lifesciadvisors.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/pulmatrix-announces-publication-demonstrating-reduction-of-bioaerosols-with-fend-an-otc-nasal-hygiene-product-designed-to-cleanse-airways-of-airborne-particles-301141922.html
SOURCE Pulmatrix, Inc.
FAQ
What are the key findings of the recent FEND study conducted by Pulmatrix?
How does Pulmatrix's FEND product function?
What is the significance of Pulmatrix licensing NasoCalm formulations to Sensory Cloud?
When did Pulmatrix announce the publication of the FEND study?
What is the stock symbol for Pulmatrix?
